FDA Recommends Separate Manufacturing For Sensitizing Non-Penicillin Beta-Lactams
This article was originally published in The Pink Sheet Daily
Executive Summary
In comments on the draft guidance, though, some firms want clearer strictures from the agency, while others seek more flexibility.